Epstein-Barr virus associated lymphoma represents a complex group of blood cancers where one of the world’s most common viruses plays a role in transforming healthy immune cells into cancerous ones, affecting people across all age groups and backgrounds.

Epidemiology

Epstein-Barr virus associated lymphoma occurs when the Epstein-Barr virus infects and transforms certain white blood cells, leading to the development of various types of lymphomas. The virus itself is remarkably widespread throughout the world. Approximately 90 to 95% of adults globally are infected with this virus at some point in their lives, making it one of the most common human viruses.^[1] In the United States specifically, around 50% of children up to 5 years of age and about 95% of adults have experienced an EBV infection during their lifetime.^[5]

While the virus is extremely common, the development of lymphoma associated with EBV is relatively rare. The chance of any individual person developing an EBV-related lymphoma is low and depends on multiple factors including ethnic background, geographic location, genetic makeup, immune system function, and other infections.^[7] However, certain populations face higher risks. The geographic pattern of these lymphomas varies significantly. For example, in areas where malaria is continuously present, primary EBV infection is followed by a period of a few years where there is an increased tendency to develop EBV-positive Burkitt lymphoma.^[7]

The age and circumstances of infection also influence lymphoma risk. In Europe and North America, primary EBV infection that causes infectious mononucleosis (commonly known as “mono” or the “kissing disease”) is followed within 6 months to 10 years by an increased risk of developing EBV-positive Hodgkin lymphoma.^[7] The proportion of lymphomas that are EBV-positive varies by type. Around 30% of Hodgkin lymphoma cases in North America are EBV-positive, while certain other lymphomas, such as endemic Burkitt lymphoma or HIV-associated primary central nervous system lymphoma, are EBV-positive in virtually 100% of cases.^[7]

Causes

The root cause of Epstein-Barr virus associated lymphoma lies in the virus’s ability to infect and persist in certain white blood cells. EBV is a member of the herpes virus family, specifically classified as human herpesvirus 4.^[5] Once a person becomes infected with EBV, the virus establishes a lifelong presence in their body, remaining dormant or inactive in a small fraction of B lymphocytes, which are a type of white blood cell that normally helps fight infections.^[7]

The virus primarily targets B lymphocytes, the white blood cells responsible for producing antibodies to fight infections. When EBV infects these cells, it attaches to them and can interfere with their normal function.^[5] The virus has powerful growth-transforming abilities and can cause infected B cells to divide excessively and abnormally.^[4] In most healthy people, the immune system keeps these infected cells under control. However, when the balance shifts, lymphoma can develop.

The presence of EBV in lymphoma tumor cells indicates that these cancers depend on the virus for their development. Scientists know this because the virus’s genetic material exists as circular structures within the cancer cells, and these structures would be lost over time unless they provided the cells with some growth or survival advantage.^[2] The virus can become integrated into the cell’s own DNA in rare cases, but usually remains as separate circular genetic material that replicates along with the cell.^[2]

Risk Factors

Several groups of people face elevated risk for developing Epstein-Barr virus associated lymphoma. The most significant risk factor involves problems with the immune system. People whose immune systems are weakened or not functioning properly have a much higher likelihood of developing EBV-related lymphomas. This includes individuals with HIV infection, those born with congenital immunodeficiencies (inherited conditions affecting immune function), people receiving immunosuppressive medications after organ transplants, and those with chronic active EBV infection.^[7]

Post-transplant patients represent a particularly high-risk group. After receiving an organ transplant, patients must take medications that suppress their immune system to prevent rejection of the new organ. This immunosuppression creates an environment where EBV-infected cells can grow unchecked, leading to post-transplant lymphoproliferative disorder (a condition where lymphoid cells multiply excessively after transplant), which is usually EBV-positive, especially when it occurs very early after the transplant procedure.^[7]

Geographic location and ethnicity also play roles in risk. People living in areas where malaria is constantly present face increased risk of developing EBV-positive Burkitt lymphoma following their initial EBV infection.^[7] The specific interaction between the malaria parasite and the virus that leads to lymphoma development is still not fully understood by scientists, but the association is clear in these regions.

The timing and severity of the initial EBV infection can influence later cancer risk. People who develop infectious mononucleosis (mono) during their teenage or young adult years have an elevated risk of developing EBV-positive Hodgkin lymphoma in the following months to years.^[7] Additionally, certain events can trigger the dormant virus to reactivate, including stress, a weakened immune system, menopause, or hormone changes.^[5] While reactivation typically causes no symptoms in healthy individuals, it can lead to serious complications in those with compromised immune function.

Age-related immune changes may also contribute to risk. Some research suggests that immunosenescence, the gradual deterioration of the immune system with aging, is associated with EBV-positive forms of certain lymphomas that are rarely EBV-related in younger people.^[7] Chronic inflammation, regardless of cause, has been linked to increased likelihood of EBV-positive lymphomas as well.^[7]

Symptoms

The symptoms of Epstein-Barr virus associated lymphoma vary depending on the specific type of lymphoma and where it develops in the body. Because lymphomas are cancers of the lymphatic system, which is spread throughout the body, symptoms can appear in many different areas. Common symptoms often mirror those seen in other types of lymphoma and may include swollen lymph nodes, which typically appear as lumps in the neck, armpits, or groin. These swollen nodes are usually painless but may cause discomfort if they press on nearby structures.

Many people with EBV-associated lymphomas experience systemic symptoms that affect the whole body. Fever without an obvious infection source is common, as is profound fatigue that doesn’t improve with rest. Unexplained weight loss, often defined as losing more than 10% of body weight over six months without trying, frequently occurs. Night sweats severe enough to soak through bedclothes are another characteristic symptom. These systemic symptoms collectively indicate that the lymphoma is affecting the body’s overall function.

Depending on the lymphoma’s location, people may experience additional specific symptoms. If the lymphoma affects the abdomen, symptoms might include abdominal pain or swelling, feeling full after eating only small amounts of food, or digestive problems. Lymphomas in the chest can cause coughing, difficulty breathing, or chest pain. When lymphomas affect the bone marrow (the soft tissue inside bones where blood cells are made), people may develop anemia (low red blood cell count causing fatigue and weakness), easy bruising or bleeding due to low platelet counts, or frequent infections from decreased white blood cell function.

Some types of EBV-associated lymphomas produce unique symptoms related to where they develop. For instance, nasopharyngeal carcinoma, a cancer of the upper throat strongly linked to EBV, can cause nosebleeds, nasal obstruction, hearing problems, or facial numbness. Extranodal (outside the lymph nodes) lymphomas affecting the skin might present as rashes, lumps, or ulcers on the skin surface.

Prevention

Preventing Epstein-Barr virus associated lymphoma presents challenges because the virus itself is so widespread and common in the population. Since over 90% of adults are infected with EBV, avoiding infection entirely is nearly impossible for most people. However, understanding transmission routes can help reduce risk, particularly for those who have not yet been infected.

The virus spreads primarily through close personal contact with bodily fluids, especially saliva. The main transmission routes include kissing, coughing or sneezing near others, sharing objects that come into contact with saliva such as toothbrushes, utensils, cups, or items that children might put in their mouths or drool on, and sexual contact through blood and semen.^[5] The virus can also spread through blood transfusions or organ transplants, though these routes are less common.^[5] People infected with EBV can spread the virus even when they have no symptoms, and the virus is particularly contagious during the incubation period (the four to six weeks between when someone is exposed to the virus and when symptoms appear).^[5]

For people at high risk of developing EBV-associated lymphomas, particularly those with weakened immune systems, different prevention strategies become important. Organ transplant recipients may benefit from careful monitoring of EBV levels in their blood, which can help doctors detect potential problems early before lymphoma develops. Some transplant centers use preventive strategies to reduce the risk of post-transplant lymphoproliferative disorder.

Maintaining a healthy immune system throughout life may help reduce the risk of EBV reactivation and associated complications. This includes managing chronic conditions properly, avoiding unnecessary immunosuppression when possible, treating HIV infection with appropriate antiretroviral therapy to maintain immune function, and addressing any identified immune deficiencies with medical care.

For people already infected with EBV, which includes most adults, the focus shifts to monitoring and early detection rather than prevention of infection. Being aware of symptoms that might indicate lymphoma, particularly in high-risk groups, allows for earlier diagnosis and treatment when problems do arise. Regular medical care and discussing any concerning symptoms with healthcare providers can facilitate early detection.

Currently, there is no vaccine available to prevent Epstein-Barr virus infection. Research into developing an EBV vaccine continues, as such a vaccine could potentially reduce not only infectious mononucleosis cases but also the burden of EBV-associated cancers and lymphomas in the future.

Pathophysiology

The development of Epstein-Barr virus associated lymphoma involves complex changes in how cells normally function. Understanding these changes helps explain how a common, usually harmless virus can occasionally lead to cancer. The process begins when EBV infects B lymphocytes, the white blood cells that normally produce antibodies to fight infections.

Once inside a B cell, EBV can follow different paths. In healthy people with functioning immune systems, the virus establishes what scientists call a latent infection, where it remains quietly present without actively producing new virus particles. During this latent state, the virus expresses different patterns of proteins depending on the type of cell it infects and the immune environment. In some EBV-associated lymphomas, such as endemic Burkitt lymphoma, tumor cells typically express only a single viral protein called Epstein-Barr nuclear antigen-1 (EBNA-1). In contrast, Hodgkin lymphoma tumors express EBNA-1 along with viral latency membrane proteins (LMP-1 and LMP-2), which are proteins expressed during the virus’s dormant state.^[7]

These viral proteins fundamentally alter how infected cells behave. EBV has powerful growth-transforming abilities that cause infected B cells to divide and multiply excessively. The virus produces proteins like latent membrane protein 1 (LMP1) that can directly transform B lymphocytes and promote their survival and growth.^[13] This transformation gives infected cells advantages over normal cells, allowing them to survive longer and divide more frequently than they should.

The virus also causes genomic instability, meaning it makes the cell’s genetic material more prone to errors and changes. Over many years of latency and occasional reactivation, these accumulated genetic changes can contribute to cancer development.^[13] The restricted protein expression pattern that EBV uses in many lymphomas allows the viral DNA to persist in cells while evading recognition by the immune system.^[7] This immune evasion is crucial because it prevents the body’s natural defenses from eliminating infected cells.

In healthy individuals, the immune system constantly monitors and controls EBV-infected cells. Specialized immune cells called cytotoxic T lymphocytes recognize and destroy cells infected with EBV before they can cause problems. The balance between the virus-driven proliferation of infected cells and immune system control determines whether lymphoma develops. When this balance is disrupted, such as in people with weakened immune systems, EBV-infected cells can grow unchecked and eventually transform into lymphoma.

The pathophysiology differs somewhat depending on the type of lymphoma. While most EBV-associated lymphomas involve B cells, the virus can also infect T cells and natural killer (NK) cells, leading to different types of lymphomas with distinct characteristics.^[6] When EBV infects these cell types, particularly in Asia and South America, it can cause chronic active EBV disease characterized by fever, liver problems, enlarged spleen, and other complications that can progress to lymphoma.^[16]

Patients with chronic active EBV often have elevated levels of inflammatory molecules in their blood, including interleukins and other cytokines that promote inflammation throughout the body.^[16] These inflammatory signals contribute to symptoms and can further impair immune function, creating a cycle where the immune system becomes progressively less able to control the virus and infected cells.